REMEGEN (09995) surged over 8%. As of press time, the stock was up 8.29% to HK$115, with a trading volume of HK$222 million.

On the news front, REMEGEN announced on September 18 that clinical data from the China Phase III study of its self-developed, globally first-in-class BLyS/APRIL dual-target fusion protein innovative drug Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been successfully selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data used to validate long-term efficacy was selected. The annual meeting will be held from October 29 to November 1, local time, at the Hilton San Francisco Union Square in California, USA.

Additionally, REMEGEN stated during a recent earnings briefing that in August 2021, the company entered into a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.). Under this agreement, the company licensed the global development and commercialization rights of Disitamab vedotin (code: RC48) in regions outside REMEGEN's territory (i.e., all regions except Japan, Singapore, and other Asian areas). Currently, RC48's overseas clinical trials are being advanced by Pfizer as planned.